Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Entinostat for treatment of solid tumors and hematologic malignancies.

Knipstein J, Gore L.

Expert Opin Investig Drugs. 2011 Oct;20(10):1455-67. doi: 10.1517/13543784.2011.613822. Epub 2011 Sep 2. Review.

PMID:
21888556
2.

Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.

Ruiz R, Raez LE, Rolfo C.

Expert Opin Investig Drugs. 2015;24(8):1101-9. doi: 10.1517/13543784.2015.1056779. Epub 2015 Jun 22. Review.

PMID:
26098363
3.

Clinical studies of histone deacetylase inhibitors.

Prince HM, Bishton MJ, Harrison SJ.

Clin Cancer Res. 2009 Jun 15;15(12):3958-69. doi: 10.1158/1078-0432.CCR-08-2785. Epub 2009 Jun 9. Review.

4.

Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.

Boumber Y, Younes A, Garcia-Manero G.

Expert Opin Investig Drugs. 2011 Jun;20(6):823-9. doi: 10.1517/13543784.2011.577737. Epub 2011 May 10. Review.

5.

Histone deacetylase inhibitors in the treatment of hematological malignancies.

Petrella A, Fontanella B, Carratù A, Bizzarro V, Rodriquez M, Parente L.

Mini Rev Med Chem. 2011 Jun;11(6):519-27. Review.

PMID:
21561404
6.

Histone deacetylase inhibitors in lymphoma and solid malignancies.

Rasheed W, Bishton M, Johnstone RW, Prince HM.

Expert Rev Anticancer Ther. 2008 Mar;8(3):413-32. doi: 10.1586/14737140.8.3.413. Review.

PMID:
18366289
7.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R.

PLoS One. 2012;7(1):e30815. doi: 10.1371/journal.pone.0030815. Epub 2012 Jan 27.

8.

Panobinostat in lymphoid and myeloid malignancies.

Khot A, Dickinson M, Prince HM.

Expert Opin Investig Drugs. 2013 Sep;22(9):1211-23. doi: 10.1517/13543784.2013.815165. Epub 2013 Jul 3. Review.

PMID:
23826641
9.

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.

Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D.

Melanoma Res. 2008 Aug;18(4):274-8. doi: 10.1097/CMR.0b013e328307c248.

PMID:
18626312
10.

Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.

Slingerland M, Guchelaar HJ, Gelderblom H.

Anticancer Drugs. 2014 Feb;25(2):140-9. doi: 10.1097/CAD.0000000000000040. Review.

PMID:
24185382
11.

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.

Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA.

Br J Cancer. 2012 Jan 3;106(1):77-84. doi: 10.1038/bjc.2011.527. Epub 2011 Dec 1.

12.

Epigenetic therapy of lymphoma using histone deacetylase inhibitors.

Cotto M, Cabanillas F, Tirado M, García MV, Pacheco E.

Clin Transl Oncol. 2010 Jun;12(6):401-9. doi: 10.1007/s12094-010-0527-3. Review.

PMID:
20534395
13.

Histone deacetylases and epigenetic therapies of hematological malignancies.

Mercurio C, Minucci S, Pelicci PG.

Pharmacol Res. 2010 Jul;62(1):18-34. doi: 10.1016/j.phrs.2010.02.010. Epub 2010 Feb 26. Review.

PMID:
20219679
14.

Histone deacetylase inhibitors: a patent review (2009 - 2011).

Carafa V, Miceli M, Altucci L, Nebbioso A.

Expert Opin Ther Pat. 2013 Jan;23(1):1-17. doi: 10.1517/13543776.2013.736493. Epub 2012 Oct 25. Review.

PMID:
23094822
15.

Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents.

Moradei O, Vaisburg A, Martell RE.

Curr Top Med Chem. 2008;8(10):841-58. Review.

PMID:
18673170
16.

The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine.

Liu HB, Mayes PA, Perlmutter P, McKendrick JJ, Dear AE.

Int J Oncol. 2011 May;38(5):1421-5. doi: 10.3892/ijo.2011.914. Epub 2011 Jan 20.

PMID:
21253674
17.

SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.

Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD, Oganesian A, Taverna P, Belinsky SA.

Int J Cancer. 2014 Nov 1;135(9):2223-31. doi: 10.1002/ijc.28865. Epub 2014 Apr 5.

18.

Romidepsin: a novel histone deacetylase inhibitor for cancer.

Bertino EM, Otterson GA.

Expert Opin Investig Drugs. 2011 Aug;20(8):1151-8. doi: 10.1517/13543784.2011.594437. Epub 2011 Jun 24. Review.

PMID:
21699444
19.

Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.

Botrugno OA, Santoro F, Minucci S.

Cancer Lett. 2009 Aug 8;280(2):134-44. doi: 10.1016/j.canlet.2009.02.027. Epub 2009 Apr 2. Review.

PMID:
19345000
20.

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

Qiu T, Zhou L, Zhu W, Wang T, Wang J, Shu Y, Liu P.

Future Oncol. 2013 Feb;9(2):255-69. doi: 10.2217/fon.12.173. Review.

PMID:
23414475

Supplemental Content

Support Center